Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
Fiche publication
Date publication
juillet 2017
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, Phelip JM, Peyrin-Biroulet L, Colombel JF, Del Tedesco E, Paul S, Flourie B
Lien Pubmed
Résumé
Infliximab (IFX) combined with azathioprine (AZA) is more effective than IFX monotherapy in inflammatory bowel disease (IBD).
Mots clés
Adult, Aged, Antirheumatic Agents, administration & dosage, Azathioprine, administration & dosage, Clinical Protocols, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Inflammatory Bowel Diseases, drug therapy, Infliximab, administration & dosage, Male, Middle Aged, Prospective Studies, Young Adult
Référence
Aliment. Pharmacol. Ther.. 2017 07;46(2):142-149